Cargando…
Management of Autoimmune Status Epilepticus
Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a ra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954092/ https://www.ncbi.nlm.nih.gov/pubmed/29867707 http://dx.doi.org/10.3389/fneur.2018.00259 |
_version_ | 1783323453161472000 |
---|---|
author | Kirmani, Batool F. Barr, Donald Robinson, Diana Mungall Pranske, Zachary Fonkem, Ekokobe Benge, Jared Huang, Jason H. Ling, Geoffrey |
author_facet | Kirmani, Batool F. Barr, Donald Robinson, Diana Mungall Pranske, Zachary Fonkem, Ekokobe Benge, Jared Huang, Jason H. Ling, Geoffrey |
author_sort | Kirmani, Batool F. |
collection | PubMed |
description | Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a rare form of the disorder encountered in the intensive care unit. ASE can be refractory to anticonvulsant therapy and the symptoms include subacute onset of short-term memory loss with rapidly progressive encephalopathy, psychiatric symptoms with unexplained new-onset seizures, imaging findings, CSF pleocytosis, and availability of antibody testing makes an earlier diagnosis of ASE possible. Neuroimmunomodulatory therapies are the mainstay in the treatment of ASE. The goal is to maximize the effectiveness of anticonvulsant agents and find an optimal combination of therapies while undergoing immunomodulatory therapy to reduce morbidity and mortality. |
format | Online Article Text |
id | pubmed-5954092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59540922018-06-04 Management of Autoimmune Status Epilepticus Kirmani, Batool F. Barr, Donald Robinson, Diana Mungall Pranske, Zachary Fonkem, Ekokobe Benge, Jared Huang, Jason H. Ling, Geoffrey Front Neurol Neuroscience Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a rare form of the disorder encountered in the intensive care unit. ASE can be refractory to anticonvulsant therapy and the symptoms include subacute onset of short-term memory loss with rapidly progressive encephalopathy, psychiatric symptoms with unexplained new-onset seizures, imaging findings, CSF pleocytosis, and availability of antibody testing makes an earlier diagnosis of ASE possible. Neuroimmunomodulatory therapies are the mainstay in the treatment of ASE. The goal is to maximize the effectiveness of anticonvulsant agents and find an optimal combination of therapies while undergoing immunomodulatory therapy to reduce morbidity and mortality. Frontiers Media S.A. 2018-05-09 /pmc/articles/PMC5954092/ /pubmed/29867707 http://dx.doi.org/10.3389/fneur.2018.00259 Text en Copyright © 2018 Kirmani, Barr, Robinson, Pranske, Fonkem, Benge, Huang and Ling. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Kirmani, Batool F. Barr, Donald Robinson, Diana Mungall Pranske, Zachary Fonkem, Ekokobe Benge, Jared Huang, Jason H. Ling, Geoffrey Management of Autoimmune Status Epilepticus |
title | Management of Autoimmune Status Epilepticus |
title_full | Management of Autoimmune Status Epilepticus |
title_fullStr | Management of Autoimmune Status Epilepticus |
title_full_unstemmed | Management of Autoimmune Status Epilepticus |
title_short | Management of Autoimmune Status Epilepticus |
title_sort | management of autoimmune status epilepticus |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954092/ https://www.ncbi.nlm.nih.gov/pubmed/29867707 http://dx.doi.org/10.3389/fneur.2018.00259 |
work_keys_str_mv | AT kirmanibatoolf managementofautoimmunestatusepilepticus AT barrdonald managementofautoimmunestatusepilepticus AT robinsondianamungall managementofautoimmunestatusepilepticus AT pranskezachary managementofautoimmunestatusepilepticus AT fonkemekokobe managementofautoimmunestatusepilepticus AT bengejared managementofautoimmunestatusepilepticus AT huangjasonh managementofautoimmunestatusepilepticus AT linggeoffrey managementofautoimmunestatusepilepticus |